M
Magenta Therapeutics Inc
F:3MT
Magenta Therapeutics Inc
F:3MT
Price:
11.136
EUR
0.29%
Market Cap:
€368.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Magenta Therapeutics Inc
F:3MT
|
US |
|
Atlantica Sustainable Infrastructure PLC
NASDAQ:AY
|
UK |
|
Endeavour Silver Corp
TSX:EDR
|
CA |
|
A
|
Asia Biomass PCL
SET:ABM
|
TH |
|
W
|
Win Hanverky Holdings Ltd
HKEX:3322
|
HK |
|
Eshallgo Inc
NASDAQ:EHGO
|
CN |
|
Camtek Ltd
F:CMZ
|
IL |
|
Rosseti Lenenergo PAO
MOEX:LSNG
|
RU |
|
W
|
Wemade Max Co Ltd
KOSDAQ:101730
|
KR |
|
Baotailong New Materials Co Ltd
SSE:601011
|
CN |
|
Procter & Gamble Co
NYSE:PG
|
US |
|
O
|
Obic Co Ltd
F:OBL
|
JP |
|
G
|
GRIPM Advanced Materials Co Ltd
SSE:688456
|
CN |
|
S
|
Societe Generale SA
F:SGE
|
FR |
|
TYMLEZ Group Ltd
ASX:TYM
|
AU |
|
Republic Bancorp Inc
NASDAQ:RBCAA
|
US |
|
Dianomi PLC
LSE:DNM
|
UK |
|
Niox Group PLC
LSE:NIOX
|
UK |
|
P
|
Pfizer Inc
SWB:PFE
|
US |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of 3MT.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
3MT
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
3MT Competitors Multiples
Magenta Therapeutics Inc Competitors
Magenta Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
Magenta Therapeutics Inc
F:3MT
|
368.6m EUR | 0 | -5.7 | -4.3 | -4.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.1B USD | 6.2 | 90.8 | 15 | 20.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.1B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 9.5 | 28.7 | 21.6 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.2B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.5B EUR | 11.1 | 35.7 | 38.7 | 39.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
